The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 26, 2020

Filed:

May. 23, 2017
Applicant:

Maxcyte, Inc., Gaithersburg, MD (US);

Inventors:

Linhong Li, North Potomac, MD (US);

Madhusudan V. Peshwa, Boyds, MD (US);

Assignee:

Maxcyte, Inc., Gaithersburg, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/00 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); A61K 39/395 (2006.01); C12N 13/00 (2006.01); C12N 15/85 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); C12N 5/0634 (2013.01); C12N 5/0646 (2013.01); C12N 13/00 (2013.01); C12N 15/85 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.


Find Patent Forward Citations

Loading…